Literature DB >> 22360810

Reverse TCA cycle flux through isocitrate dehydrogenases 1 and 2 is required for lipogenesis in hypoxic melanoma cells.

Fabian V Filipp1, David A Scott, Ze'ev A Ronai, Andrei L Osterman, Jeffrey W Smith.   

Abstract

The tricarboxylic acid (TCA) cycle is the central hub of oxidative metabolism, running in the classic forward direction to provide carbon for biosynthesis and reducing agents for generation of ATP. Our metabolic tracer studies in melanoma cells showed that in hypoxic conditions the TCA cycle is largely disconnected from glycolysis. By studying the TCA branch point metabolites, acetyl CoA and citrate, as well as the metabolic endpoint glutamine and fatty acids, we developed a comprehensive picture of the rewiring of the TCA cycle that occurs in hypoxia. Hypoxic tumor cells maintain proliferation by running the TCA cycle in reverse. The source of carbon for acetyl CoA, citrate, and fatty acids switches from glucose in normoxia to glutamine in hypoxia. This hypoxic flux from glutamine into fatty acids is mediated by reductive carboxylation. This reductive carboxylation is catalyzed by two isocitrate dehydrogenases, IDH1 and IDH2. Their combined action is necessary and sufficient to effect the reverse TCA flux and maintain cellular viability. Published 2012. This article is a U.S. Government work and is in the public domain in the USA.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22360810      PMCID: PMC3329592          DOI: 10.1111/j.1755-148X.2012.00989.x

Source DB:  PubMed          Journal:  Pigment Cell Melanoma Res        ISSN: 1755-1471            Impact factor:   4.159


  26 in total

1.  Serum isocitrate dehydrogenase in liver disease and some other conditions.

Authors:  J L BELL; S SHALDON; D N BARON
Journal:  Clin Sci       Date:  1962-08       Impact factor: 6.124

2.  On the origin of cancer cells.

Authors:  O WARBURG
Journal:  Science       Date:  1956-02-24       Impact factor: 47.728

3.  Subcellular distribution of the isoenzymes of NADP isocitrate dehydrogenase in rat liver and heart.

Authors:  J L Bell; D N Baron
Journal:  Enzymol Biol Clin (Basel)       Date:  1968

Review 4.  Glycolysis, glutaminolysis and cell proliferation.

Authors:  W L McKeehan
Journal:  Cell Biol Int Rep       Date:  1982-07

Review 5.  Fatty acid synthase as a potential therapeutic target in cancer.

Authors:  Richard Flavin; Stephane Peluso; Paul L Nguyen; Massimo Loda
Journal:  Future Oncol       Date:  2010-04       Impact factor: 3.404

6.  Comparative metabolic flux profiling of melanoma cell lines: beyond the Warburg effect.

Authors:  David A Scott; Adam D Richardson; Fabian V Filipp; Christine A Knutzen; Gary G Chiang; Ze'ev A Ronai; Andrei L Osterman; Jeffrey W Smith
Journal:  J Biol Chem       Date:  2011-10-13       Impact factor: 5.157

7.  HIF-1-mediated expression of pyruvate dehydrogenase kinase: a metabolic switch required for cellular adaptation to hypoxia.

Authors:  Jung-whan Kim; Irina Tchernyshyov; Gregg L Semenza; Chi V Dang
Journal:  Cell Metab       Date:  2006-03       Impact factor: 27.287

8.  Orlistat is a novel inhibitor of fatty acid synthase with antitumor activity.

Authors:  Steven J Kridel; Fumiko Axelrod; Natasha Rozenkrantz; Jeffrey W Smith
Journal:  Cancer Res       Date:  2004-03-15       Impact factor: 12.701

9.  Oncogenic K-Ras decouples glucose and glutamine metabolism to support cancer cell growth.

Authors:  Daniela Gaglio; Christian M Metallo; Paulo A Gameiro; Karsten Hiller; Lara Sala Danna; Chiara Balestrieri; Lilia Alberghina; Gregory Stephanopoulos; Ferdinando Chiaradonna
Journal:  Mol Syst Biol       Date:  2011-08-16       Impact factor: 11.429

10.  Functional genomics reveal that the serine synthesis pathway is essential in breast cancer.

Authors:  Richard Possemato; Kevin M Marks; Yoav D Shaul; Michael E Pacold; Dohoon Kim; Kıvanç Birsoy; Shalini Sethumadhavan; Hin-Koon Woo; Hyun G Jang; Abhishek K Jha; Walter W Chen; Francesca G Barrett; Nicolas Stransky; Zhi-Yang Tsun; Glenn S Cowley; Jordi Barretina; Nada Y Kalaany; Peggy P Hsu; Kathleen Ottina; Albert M Chan; Bingbing Yuan; Levi A Garraway; David E Root; Mari Mino-Kenudson; Elena F Brachtel; Edward M Driggers; David M Sabatini
Journal:  Nature       Date:  2011-08-18       Impact factor: 49.962

View more
  82 in total

Review 1.  Metabolomic signature of brain cancer.

Authors:  Renu Pandey; Laura Caflisch; Alessia Lodi; Andrew J Brenner; Stefano Tiziani
Journal:  Mol Carcinog       Date:  2017-07-17       Impact factor: 4.784

2.  Sterol Regulatory Element Binding Protein Regulates the Expression and Metabolic Functions of Wild-Type and Oncogenic IDH1.

Authors:  Stéphane J H Ricoult; Christian C Dibble; John M Asara; Brendan D Manning
Journal:  Mol Cell Biol       Date:  2016-08-26       Impact factor: 4.272

3.  Membrane lipid profile alterations are associated with the metabolic adaptation of the Caco-2 cells to aglycemic nutritional condition.

Authors:  Vera F Monteiro-Cardoso; Amélia M Silva; Maria M Oliveira; Francisco Peixoto; Romeu A Videira
Journal:  J Bioenerg Biomembr       Date:  2014-02       Impact factor: 2.945

4.  Cancer-associated isocitrate dehydrogenase 1 (IDH1) R132H mutation and d-2-hydroxyglutarate stimulate glutamine metabolism under hypoxia.

Authors:  Zachary J Reitman; Christopher G Duncan; Ethan Poteet; Ali Winters; Liang-Jun Yan; David M Gooden; Ivan Spasojevic; Laszlo G Boros; Shao-Hua Yang; Hai Yan
Journal:  J Biol Chem       Date:  2014-07-01       Impact factor: 5.157

5.  An acidic residue buried in the dimer interface of isocitrate dehydrogenase 1 (IDH1) helps regulate catalysis and pH sensitivity.

Authors:  Lucas A Luna; Zachary Lesecq; Katharine A White; An Hoang; David A Scott; Olga Zagnitko; Andrey A Bobkov; Diane L Barber; Jamie M Schiffer; Daniel G Isom; Christal D Sohl
Journal:  Biochem J       Date:  2020-08-28       Impact factor: 3.857

Review 6.  Expanding the concepts and tools of metabolic engineering to elucidate cancer metabolism.

Authors:  Mark A Keibler; Sarah-Maria Fendt; Gregory Stephanopoulos
Journal:  Biotechnol Prog       Date:  2012-10-18

7.  RNA-Binding Protein HuR Regulates Both Mutant and Wild-Type IDH1 in IDH1-Mutated Cancer.

Authors:  Mahsa Zarei; Shruti Lal; Ali Vaziri-Gohar; Kevin O'Hayer; Venugopal Gunda; Pankaj K Singh; Jonathan R Brody; Jordan M Winter
Journal:  Mol Cancer Res       Date:  2018-09-28       Impact factor: 5.852

Review 8.  Therapeutic strategies impacting cancer cell glutamine metabolism.

Authors:  Michael J Lukey; Kristin F Wilson; Richard A Cerione
Journal:  Future Med Chem       Date:  2013-09       Impact factor: 3.808

Review 9.  Glutamine-fueled mitochondrial metabolism is decoupled from glycolysis in melanoma.

Authors:  Fabian V Filipp; Boris Ratnikov; Jessica De Ingeniis; Jeffrey W Smith; Andrei L Osterman; David A Scott
Journal:  Pigment Cell Melanoma Res       Date:  2012-10-01       Impact factor: 4.693

10.  In vivo HIF-mediated reductive carboxylation is regulated by citrate levels and sensitizes VHL-deficient cells to glutamine deprivation.

Authors:  Paulo A Gameiro; Juanjuan Yang; Ana M Metelo; Rocio Pérez-Carro; Rania Baker; Zongwei Wang; Alexandra Arreola; W Kimryn Rathmell; Aria Olumi; Pilar López-Larrubia; Gregory Stephanopoulos; Othon Iliopoulos
Journal:  Cell Metab       Date:  2013-03-05       Impact factor: 27.287

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.